Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus

Journal of Clinical Biochemistry and Nutrition

Volumn 52, Issue 1, 2013, Pages 22-26

  Luévano Contreras, Claudia ^a   Garay Sevilla, Ma Eugenia ^a   Wrobel, Kazimierz ^a   Malacara, Juan M ^a   Wrobel, Katarzyna ^a  

^a UNIVERSITY OF GUANAJUATO   (Mexico)

Author keywords

Advanced glycation end products; Diabetes mellitus; Diet; Malondialdehyde; TNF

Indexed keywords

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; DIETARY ADVANCED GLYCATION END PRODUCT; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; METFORMIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTHROPOMETRY; ARTICLE; CLINICAL ARTICLE; DIABETIC PATIENT; DIETARY INTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

EID: 84872355657     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.12-40     Document Type: Article

References (26)

1. Vlassara H, Crandall J, Goldberg T, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002; 99: 15596-15601. (Pubitemid 35403978)
2. Weiss MF, Erhard P, Kader-Attia FA, et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 2000; 57: 2571-2585. (Pubitemid 30340756)
3. Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des 2007; 13: 2832-2836. (Pubitemid 350130976)
4. Golberg T, Cai W, Peppa M, et al. Advanced glycation end products in commonly consumed foods. J Am Diet Assoc 2004; 104: 1287-1291. (Pubitemid 39036519)
5. Henle T. Protein-bound advanced glycation endproducts (AGEs) as bioactive amino acid derrivatives in foods. Amino Acids 2005; 29: 313-322. (Pubitemid 41813489)
6. Ahmed N, Mirshekar-Syahakal B, Kennish L, Karachalias N, Babaci-Jadidi R, Thornalley PJ. Assay of advanced glycation endproducts in selected beverage and food by liquid chromatography with tandem mass spectrometric detection. Mol Nutr Food Res 2005; 49: 691-699. (Pubitemid 41008207)
7. Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010; 110: 911-916.
8. Uribarri J, Peppa M, Cai W, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003; 14: 728-731. (Pubitemid 36246017)
9. Cai W, Gao Q, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002; 8: 337-346. (Pubitemid 35346213)
10. Uribarri J, Cai W, Sandu O, Peppa M, Golberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann NY Acad Sci 2005; 1043: 461-466. (Pubitemid 41123934)
11. Sebeková K, Somoza V. Dietary advanced glycation endproducts (AGEs) and their health effects - PRO. Mol Nutr Food Res 2007; 51: 1079-1084. (Pubitemid 47522798)
12. Vlassara H, Striker GE. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol 2011; 7: 527-539.
13. Negrean M, Stirban A, Stratman B, et al. Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 2007; 85: 1236-1243. (Pubitemid 46740464)
14. Uribarri J, Cai W, Peppa M, et al. Circulation glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007; 62: 427-433. (Pubitemid 47065712)
15. Uribarri J, Cai W, Ramadas M, et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 2011; 34: 1610-1616.
16. Wróbel K, Wróbel K, Garay-Sevilla ME, Nava LE, Malacara JM. Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorimetric detection in flow system. Clin Chem 1997; 43: 1563-1569. (Pubitemid 27396348)
17. Serafín Muñoz AH, Preciado-Puga M, Wrobel K, Garay-Sevilla ME, Wrobel K. Microassay for malondialdehyde in human serum by extraction-spectrophotometry using an internal standard. Microchimica Acta 2004; 148: 285-291. (Pubitemid 40109974)
18. Chao PC, Huang CN, Hsu CC, Yin MG, Guo YR. Association of dietary AGEs with circulating AGEs, glycated LDL, IL-1α and MCP-1 levels in type 2 diabetic patients. Eur J Nutr 2010; 49: 429-434.
19. Vlassara H, Cai W, Goodman S, et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 2009; 94: 4483-4491.
20. Lin RY, Choudhury RP, Cai W, et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003; 168: 213-220. (Pubitemid 36703319)
21. Thornalley PJ, Battah S, Ahmed N, et al. Quantitative screening of advanced glycation endproducts in cellurar and extracellular proteins by tandem mass spectrometry. Biochem J 2003; 375: 581-592. (Pubitemid 37433506)
22. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003; 25: 275-281. (Pubitemid 38041265)
23. Garay-Sevilla ME, Regalado JC, Malacara JM, et al. Advanced glycosylation end products in skin, serum, saliva and urine and its association with complications of patients with type 2 diabetes mellitus. J Endocrinol Invest 2005; 28: 223-230. (Pubitemid 43162769)
24. Galler A, Müeller G, Schinzel R, Kratzsch J, Kiess W, Münch G. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and n-epsilon- (carboxymethyl)lysine ELISA. Diabetes Care 2003; 26: 2609-2615. (Pubitemid 37052108)
25. Ahmed KA, Muniandy S, Ismail IS. Role of N-(carboxymethyl)lysine in the development of ischemic heart disease in type 2 diabetes mellitus. J Clin Biochem Nutr 2007; 41: 97-105. (Pubitemid 47529305)
26. Baumann M, Stehouwer C, Scheijen J, et al. N epsilon-(carboxymethyl) lysine during the early development of hypertension. Ann NY Acad Sci 2008; 1126: 201-204.